Vyvanse does nothing until your blood chops off an amino acid
Lisdexamfetamine, sold as Vyvanse or Elvanse, is inert when swallowed. It is dextroamphetamine chemically bolted to the amino acid lysine, and enzymes in the blood must snip that bond to release the stimulant. Effects arrive within about 90 minutes and can last up to 14 hours.
Doctors prescribe it for attention deficit hyperactivity disorder at any age from childhood up, and for adults whose binge eating disorder is moderate or severe. Approved in the United States in 2007 and the European Union in 2012, it ranked 76th among American prescriptions in 2023, with more than 9 million filled. Because it carries a high potential for misuse, it is tightly controlled: Schedule II in the United States, Class B in the United Kingdom and Schedule 8 in Australia.
ADHD models point to weakened dopamine and norepinephrine signalling in circuits feeding the prefrontal cortex, and stimulants work by boosting activity there; roughly 80 percent of people who take them see symptoms improve. A 2019 systematic review rated lisdexamfetamine the most effective treatment for adult ADHD, and a 2025 analysis of 113 randomised trials found stimulants were the only intervention with robust short-term benefit. Reviews of brain imaging suggest long-term therapeutic use may reduce structural differences seen in ADHD, although high doses harm the dopamine system in some animals.
As of July 2024 it was the only medicine approved by American and Australian regulators for binge eating disorder. It does curb appetite, acting in the lateral hypothalamus, but reviewers think the main benefit comes from sharper cognitive control that helps override the urge to binge. Supporting that view, ordinary appetite suppressants and anti-obesity drugs cause weight loss without easing the disorder much. Trials at 50 to 70 mg showed fewer binge days per week, sustained over a 12-month extension study.
Common side effects include raised blood pressure, lost appetite, anxiety, poor sleep, irritability and nausea. Rarer dangers include mania, psychosis and sudden cardiac death in people with existing heart disease, and combining it with some other drugs can trigger serotonin syndrome. The manufacturer advises against use while breastfeeding because the active metabolite passes into milk.
Source: Lisdexamfetamine
